Oncternal Therapeutics Inc's Customers Performance

Name: Oncternal Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

ONCT

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


ONCT's Source of Revenues		During the corresponding time, Oncternal Therapeutics Inc recorded a revenue increase by 175.98 % year on year, sequentially revenue fell by -38.33 %. While revenue at the Oncternal Therapeutics Inc 's corporate clients • List of ONCT Customers

for the same period Oncternal Therapeutics Inc recorded revenue increase by 175.98 % year on year, sequentially revenue fell by -38.33 %.

• List of ONCT Customers

Oncternal Therapeutics Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Oncternal Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Oncternal Therapeutics Inc Contracts

Oncternal Therapeutics Advances Treatment for Metastatic Castration-Resistant Prostate Cancer with ONCT-534 Study...

Advancing Treatment for Metastatic Castration-Resistant Prostate Cancer: Oncternal s Progress with ONCT-534Oncternal Therapeutics, a renowned clinical-stage biopharmaceutical company focused on developing innovative oncology therapies, has recently announced significant progress in their Phase 1/2 study of ONCT-534 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients who have relapsed or are refractory to approved androgen receptor pathway inhibitors.Enrollment for the sixth dose cohort of the trial has been successfully completed, and dosing has been initiated. Patients in this cohort will receive a daily oral dose of 1200 mg of ONCT-534, which is the company s dual-action ...

Oncternal Therapeutics Progresses Robustly in ONCT-534 Phase 1/2 Prostate Cancer Study and Updates on ONCT-808 B-cell Lymphoma Trial

The preeminent biopharmaceutical entity, Oncternal Therapeutics, has constantly pushed the bounds of innovation in its dogged pursuit of creating novel oncology therapies. The burgeoning clinical-stage biotech announced two significant milestones in its ongoing Phase 1/2 studies employing its dual-action androgen receptor inhibitor, ONCT-534, specifically targeting patients who have relapsed or exhibit resistance to approved androgen receptor pathway inhibitors (ARPI).Almost three months after confirming the enrollment of its fourth patient into the Phase 1/2 study of ONCT-534, and initiating the third dosage cohort receiving 160mg of the ARPI daily, Oncternal Therapeutics demonstrated impressive forward mom...

ONCT's Stock Performance relative to it's Customers

ONCT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Oncternal Therapeutics Inc	2.22	2.16	-34.58	24
SUBTOTAL	0.00	0.00	0.00	-

Sources: Oncternal Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Oncternal Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Oncternal Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.